Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, human normal immunoglobulin (Privigen®) cannot be endorsed for use within NHS Wales for immunomodulation in adults, and children and adolescents (0-18 years) in chronic inflammatory demyelinating polyneuropathy (CIDP). Only limited experience is available of use of intravenous immunoglobulins in children with CIDP. |
||
|
||
Medicine details |
||
| Medicine name | human normal immunoglobulin (Privigen®) | |
| Formulation | 100 mg/ml solution for infusion | |
| Reference number | 1979 | |
| Indication | Immunomodulation in adults, and children and adolescents (0-18 years) in chronic inflammatory demyelinating polyneuropathy (CIDP). Only limited experience is available of use of intravenous immunoglobulins in children with CIDP |
|
| Company | CSL Behring UK Ltd | |
| BNF chapter | Immunological products & vaccines | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 02/12/2013 | |